Loading...
Docoh

Qualigen Therapeutics (QLGN)

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack System, which has been used successfully in diagnostics for almost 20 years. The FastPack menu includes tests for cancer, men's health, hormone function and vitamin D status. The Company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. The foundational aptamer of ALAN, AS1411, is also being studied for use in treating viral-based infectious diseases, including COVID-19. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen's facility in Carlsbad, California is FDA and ISO Certified and its FastPack product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC.

Company profile

QLGN stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

15 Aug 22
1 Oct 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 5.72K 5.72K 5.72K 5.72K 5.72K
Cash burn (monthly) 1.27M 1.38M 1.67M 1.32M 1.15M
Cash used (since last report) 3.88M 4.22M 5.1M 4.02M 3.51M
Cash remaining -3.88M -4.22M -5.1M -4.02M -3.51M
Runway (months of cash) -3.1 -3.1 -3.1 -3.1 -3.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
11 Jul 22 Amy S. Broidrick Stock Option Common Stock Grant Acquire A No No 0.5136 130,000 66.77K 130,000
11 Jul 22 Korenberg Matthew E Stock Option Common Stock Grant Acquire A No No 0.5136 40,000 20.54K 40,000
11 Jul 22 Christopher L. Lotz Stock Option Common Stock Grant Acquire A No No 0.5136 100,000 51.36K 100,000
11 Jul 22 Tariq Arshad Stock Option Common Stock Grant Acquire A No No 0.5136 102,000 52.39K 102,000
11 Jul 22 Ritter Ira E. Stock Option Common Stock Grant Acquire A No No 0.5136 40,000 20.54K 40,000
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: absence, acquiree, advertising, annum, Antimicrobial, assigned, assimilation, assumption, AST, attention, bear, bearing, commensurate, component, Concurrently, consummated, critical, daily, diligence, disrupt, diversion, dollar, domiciled, face, feasibility, FMV, forma, goodwill, inability, indefinite, innovative, intended, Israeli, meet, methodology, noncontrolling, offering, ordinary, partially, person, perspective, platform, prefunded, preliminary, presence, proprietary, purport, rationale, Regulation, reissued, relinquish, Repayment, repriced, repricing, retention, Shekel, spending, stretch, supplemental, Susceptibility, tangible, team, translated, translating, translation, unanticipated, understanding, underwritten, unexpected, unexpensed, USD, valuable, viable, write, Ziona
Removed: Lastly, nonvested, refusal, respond, size, unused, wholly